CJC-1295
Also known as Modified GRF (1-29) · Mod GRF 1-29
Studied in small numbers of humans, usually for safety and pharmacokinetics rather than whether it works. A phase 1 result says almost nothing about effectiveness.
What it is
A modified fragment of growth hormone releasing hormone with substitutions that resist enzymatic breakdown. A separate version with a drug affinity complex extends the half-life considerably; the two are often confused.
How it is thought to work
GHRH receptor agonist, increasing pulsatile growth hormone secretion.
What the studies found
-
Early human studies confirmed GH and IGF-1 increases
Phase 1 work showed dose-dependent increases in growth hormone and IGF-1 concentrations, sustained for several days with the DAC version.
-
Development did not continue
Clinical development was discontinued. Reporting at the time linked the decision to a serious adverse event in a trial participant, though the details were not fully published.
What the evidence does not show
- Human evidence is limited to early-phase pharmacology — what it does to hormone levels, not whether that produces any clinical benefit.
- No trials assessed body composition, recovery or ageing outcomes.
- The DAC and non-DAC versions have materially different pharmacokinetics and are frequently conflated.
Reported risks and adverse effects
- Reported effects include injection site reactions and flushing.
- Development discontinued; the safety picture was never completed.
- Sustained elevation of the GH axis carries theoretical concerns around glucose tolerance and neoplasia.
- Prohibited by WADA.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
Regulatory status
Not approved anywhere. Clinical development discontinued.